Irwin Naturals Inc. (CSE:IWIN) has announced its planned suite of clinic services for its chain of psychedelic mental health clinic - Irwin Naturals Emergence.
The company said it is in the early stages of a large-scale national rollup of mental health clinics, which will feature treatment with the psychedelic ketamine, a US Food and Drug Administration-approved drug used for off-label mental health therapies.
The company noted that it intends to expand treatment options at its clinics by offering a broad portfolio of powerful next-generation therapies.
READ: Irwin Naturals completes acquisition of Midwest Ketafusion in Iowa
Irwin Naturals Emergence clinics will be offering three breakthrough treatments to battle America's mental health crisis—ketamine, stellate ganglia block, and transcranial magnetic stimulation (TMS). Offerings may vary by clinic.
"We believe that, by expanding our offering, we will be able to improve patient success rates,” said CEO Klee Irwin in a statement. “Adding to these three primary treatment pillars, we will be offering talk therapy and breathwork to enhance treatment results."
Irwin added: "Our goal is two-fold. First, we want to achieve unprecedented levels of clinical effectiveness by combining treatments synergistically. Secondly, we plan to publish this data from our clinics to add to the current understanding of these treatments in the broader scientific community."
The company also said it intends to work with major third-party payors in order to reduce costs even further, making these life-changing treatments accessible to many.
CEO Irwin concluded, "We plan to work with major payors, such as veterans groups and major medical insurance carriers, to adopt policies that include psychedelic-based treatments. Most of these payors are for-profit enterprises interested in reducing medical costs."
Irwin is a best-in-class herbal supplement formulator since 1994 that is leveraging its brand to enter the cannabis and psychedelic industries. Its growing portfolio of herbal products is available in more than 100,000 retail stores across North America.
In 2018, the company first leveraged its brand to expand into the cannabis industry by launching hemp-based CBD products into the mass market. It is now leveraging its famous halo of brand trust to become one of the first household name brands to offer THC-based products and psychedelic-assisted services.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham